New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms

About this update from Medicus Pharma Ltd.

[{"type":"text","content":"NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX), a precision-guided biotech and life sciences company advancing innovative therapeutic platforms, has entered into a 12-part, one-year strategic media agreement with New to The Street to expand its national and international visibility across television, digital, and outdoor platforms.","length":374,"tagName":"p"},{"type":"text","content":"The campaign will highlight Medicus Pharma's differentiated pipeline, including SkinJect™, a localized immuno-oncology platform targeting non-melanoma skin cancers such as basal cell carcinoma and rare conditions like Gorlin Syndrome, representing a multi-billion-dollar market opportunity. The series will also feature Teverelix®, a next-generation GnRH antagonist designed for patients with advanced prostate cancer and acute urinary retention associated with enlarged prostate conditions-addressing a significant and growing global market.","length":546,"tagName":"p"},{"type":"text","content":"Under the agreement, New to The Street will produce and distribute a comprehensive media campaign designed to elevate Medicus Pharma's corporate narrative, clinical progress, and long-term growth strategy to a broad investor audience.","length":238,"tagName":"p"},{"type":"text","content":"The series will include 12 in-depth executive interviews released monthly, with each segment broadcast across Bloomberg Television in the United States, reaching approximately 124 million households, and additional features airing on FOX Business Network as sponsored programming.","length":280,"tagName":"p"},{"type":"text","content":""Our platform is built to provide public companies with consistent, high-impact visibility across television, digital, and outdoor media," said Vince Caruso, Co-Founder of New to The Street. "Medicus Pharma's innovative therapeutic platforms, particularly SkinJect™ and Teverelix®, represent meaningful advancements in high-demand clinical areas, and we are excited to support their continued growth and investor awareness."","length":448,"tagName":"p"},{"type":"text","content":"As part of the integrated campaign, Medicus Pharma will benefit from extensive commercial and digital exposure, including 80 monthly television commercial placements in the New York market during peak tra...

More updates from Medicus Pharma Ltd.